Andere talen BioCardia, Inc.

Aandelen

BCDA

US09060U5074

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3871 ^USD	+4,62%		+2,95%	-41,72%

25/04	BioCardia voltooit de inclusie van het open-label cohort van CardiAMP celtherapie voor de behandeling van chronische myocardischemie	CI
27/03	Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	09/02
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	31/01
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	03/01
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioCardia, Inc.

Aandelen

BCDA

US09060U5074

Andere talen

Filters